DNDI

Neglected patients deserve the best science.

- Influence the R&D landscape for neglected patients through political leadership for needs-driven R&D, the creation of a global fund and providing evidence on alternative R&D models

- Develop and deliver 16-18 treatments (mid-term), installing 3 new chemical entities (NCEs), covering ~10 disease areas and focussing on access and impact-measurement

The ambition is to deliver 16 to 18 treatments with EUR 650 million by 2023.

- Strengthen Research Capacity led by Regional Offices through R&D platforms in disease-endemic countries, regionally-driven initiatives and technology-transfer

DNDI forges 'inventive partnerships', in 2017 - 160 organisations, community based, public and privat, local and global have been part of the network.

Lessons Learnt:

- Careful selection of industrial partners matters for all stages of the R&D process

- End-to-end access safeguards are crucial, that is from molecule selection to post-delivery usage access needs to be guaranteed -> external policy frameworks must also include these access safeguards (cf. recommendations of the UN HLP on Access to Medicines)

- building national network of partners or regional consortia is necessary but time-consuming

- Commitment from government and including affected communities is indispensable

DNDi depends on donors. It seeks different sources of funding from governments and international organisations, Founding Partners who provide ongoing support, private foundations and large donors, and individuals. According to its website "DNDi is well-positioned to obtain the funds necessary to sufficiently support its mission, vision, and objectives, and to maintain independence."

The Friends of DNDi, a group of individuals from around the world committed to DNDi’s vision and mission, give DNDi an additional tool to strengthen and support the fundraising strategy, as well as raising awareness of the need for R&D for neglected diseases.

R&D platforms in disease-endemic countries Regionally-driven initiatives Patient access to treatments Transfer of technology

DNDI underlines three aspects for successful partnerships: to share the same vision, to focus on mutual understanding and to guaranteee involvement throughout the whole process. This enables them to Cultivate Shared Purpose & Values, Trust Situated Knowing and Be Creatively Adaptive Deepen Interdependency on Nature Preserve Relationships in Addressing Conflicts Reflect on Your Peer Governance

- perpetually royalty-free, non-exclusive, sub-licensable licenses in the specific disease areas determined in the contract

- Worldwide research and manufacturing rights are guaranteed

- partners commit to make the final product available at cost, plus a minimal margin, in all endemic countries, regardless fo their income level

- Non-exclusivity, enabling technology transfer and local production to multiply sources of production and decrease cost of product

DNDI integrates, according to Spring Gombe, access to knowledge and access to treatments while delinking the costs of R&D from the price of the final product. This is the key strategy.